Delving into the Latest Updates on Recombinant human IL-21-expressing Oncolytic Vaccinia Virus (Hangzhou Converd) with Synapse

Overview

Basic Info

Drug Type

Oncolytic virus

Synonyms

HV01

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]

Active Indication

Pancreatic CancerAdvanced SarcomaUterine Cervical Cancer+ [1]

Inactive Indication-

Originator Organization

Hangzhou Converd Co., Ltd.

Active Organization

Hangzhou Converd Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Primary purpose: To evaluate the preliminary effectiveness of hV01 single intratumoral injection per cycle in the treatment of advanced sarcoma and cervical cancer. Secondary purpose: To further evaluate the safety of hV01 single intratumoral injection per cycle. Exploratory purpose: To explore the correlation between changes in peripheral blood immune-related indicators and efficacy.

Start Date09 Apr 2025

Sponsor / Collaborator

Hangzhou Converd Co., Ltd.

NCT05914376

/ RecruitingPhase 1

A Phase I Dose Escalation Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Biological Properties of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Malignant Solid Tumors

The goal of this clinical trial is to evaluate the safety, tolerance, pharmacokinetics, and biological properties of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced solid tumors.

Start Date05 Jul 2023

Sponsor / Collaborator

Hangzhou Converd Co., Ltd.

100 Clinical Results associated with Recombinant human IL-21-expressing Oncolytic Vaccinia Virus (Hangzhou Converd)

Login to view more data

100 Translational Medicine associated with Recombinant human IL-21-expressing Oncolytic Vaccinia Virus (Hangzhou Converd)

Login to view more data

100 Patents (Medical) associated with Recombinant human IL-21-expressing Oncolytic Vaccinia Virus (Hangzhou Converd)

Login to view more data

100 Deals associated with Recombinant human IL-21-expressing Oncolytic Vaccinia Virus (Hangzhou Converd)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Phase 2	China	Hangzhou Converd Co., Ltd.	21 May 2025
Advanced Sarcoma	Phase 2	China	Hangzhou Converd Co., Ltd.	09 Apr 2025
Uterine Cervical Cancer	Phase 2	China	Hangzhou Converd Co., Ltd.	09 Apr 2025
Advanced Malignant Solid Neoplasm	Phase 1	China	Hangzhou Converd Co., Ltd.	05 Jul 2023